Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Nike Tops Earnings Estimates, Returns $2.1B To Shareholders In Q2 – $NKE $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, NIKE, Inc.’s  (NKE) fiscal 2023 financial results for its second quarter exceeded market estimates, but higher costs squeezed the company’s margins.

 Highlights for the 3 months Quarter Ended Nov 30:

  • Earnings per share of 85 cents were reported versus the 64 cents expected.
  • Revenue stood at $13.32 billion versus the $12.57 billion expected.
  • Nike reported a net income of $1.33 billion for the quarter that ended November 30 compared with $1.34 billion a year earlier.
  • Inventories were up 43% to $9.3 billion in the quarter, compared to last year.
  • The company also saw a 10% year-over-year uptick in selling and administrative expenses to $4.1 billion, mostly led by advertising and marketing costs and investment in Nike Direct as the company continues to move away from wholesalers.
  • Nike Direct sales increased 16% for the quarter at $5.4 billion and digital sales were up 25%. 
  • Nike’s sales in China, its third biggest market by revenue, dropped by 3% compared to last year.
  •  Overall retail sales in the country dropped by 5.9% in November compared to a year ago and clothes and shoe sales dropped by 15.6%.

BIKE continues to have a strong track record of investing to fuel growth and consistently increasing returns to shareholders, including 21 consecutive years of increasing dividend payouts. In the second quarter, NIKE returned approximately $2.1 billion to shareholders, including: Dividends of $480 million, up 10 percent from the prior year, Share repurchases of $1.6 billion, reflecting 16.5 million retired shares as part of the four-year, $18 billion program approved by the Board of Directors in June 2022. As of November 30, 2022, a total of 19.0 million shares have been repurchased under the program for a total of approximately $1.9 billion.

NIKE, Inc. (NKE) is the world’s top designer, marketer, and distributor of athletic footwear, equipment, apparel, and accessories. The Beaverton, Oregon-based company offers products for a wide variety of sports and fitness activities. To learn more about NIKE, Inc. (NIKE) and to continue to track its progress please visit the Vista Partners NIKE Coverage Page.


Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: Nike stock surges after earnings and revenue top expectations in CNBC)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us